Please assess the completion status of the following clinical trial:

Trial Title: Effect of Erythromycin Before Endoscopy of Patients With Subtotal Gastrectomy (STG), High Risk of Gastric Stasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who undergone STG (billroth I, billroth II, R-Y STG) within 5 years to treat gastric cancer~* Stage of T1-2N0M0~Exclusion Criteria:~* concomitant therapy with astemizole, cisapride, dihydroergotamine, ergotamine, pimozide, or terfenadine, narcotics, alpha-2-adrenergic agonist, TCA, CCB, dopamine agonist, muscarinic cholinergic antagonists, octreotide, exenatide and GLP-1 agonist, phenothiazines~* chemotherapy Hx.~* hypersensitivity to erythromycin or any component of the product~* pregnancy or lactation~* comobidity : DM, AIDS, neurologic disease(parkinsonism, multiple sclerosis, brainstem stroke or tumor, diabetic or amyloid neuropathy, or primary dysautonomias) scleroderma and other connective tissue disease, recent viral enteritis history~* recurrence

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- erythromycin (Type: EXPERIMENTAL): None
- saline (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).